(Q40753761)

23 September 2017

title

Efficacy and toxicity profile of oral topotecan in a panel of human tumour xenografts (English)

1 reference

23 September 2017

1 reference

1 reference

Michelandrea De Cesare

1

1 reference

23 September 2017

Zunino F

2

1 reference

23 September 2017

Pace S

3

1 reference

23 September 2017

Pisano C

4

1 reference

23 September 2017

Pratesi G

5

1 reference

23 September 2017

language of work or name

1 reference

1 August 2000

1 reference

European Journal of Cancer

23 September 2017

published in

1 reference

23 September 2017

volume

36

1 reference

23 September 2017

issue

12

1 reference

23 September 2017

page(s)

1558-1564

1 reference

DNA topoisomerase poisons as antitumor drugs

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900141-6

7 January 2021

The S-phase cytotoxicity of camptothecin.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900141-6

7 January 2021

Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900141-6

7 January 2021

Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900141-6

7 January 2021

Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900141-6

7 January 2021

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900141-6

7 January 2021

Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900141-6

7 January 2021

Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900141-6

7 January 2021

Comparative activity of oral and parenteral topotecan in murine tumor models: efficacy of oral topotecan

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900141-6

7 January 2021

UKCCCR guidelines for the welfare of animals in experimental neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900141-6

7 January 2021

Effects of 5-FU and cis-DDP combination on human colorectal tumor xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900141-6

7 January 2021

Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900141-6

7 January 2021

Current perspectives on camptothecins in cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900141-6

7 January 2021

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900141-6

7 January 2021

Oral chemotherapy: rationale and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900141-6

7 January 2021

10.1016/S0959-8049(00)00141-6

Identifiers

DOI

1 reference

23 September 2017

1 reference